The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | ENDURANCE trial: KRd versus VRd for initial therapy of NDMM
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the results of the ENDURANCE trial (NCT01863550), a Phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) compared to carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (NDMM). Dr Kumar reveals that VRd remains the standard triplet induction regimen in standard and intermediate-risk NDMM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
